Free Trial

Autolus Therapeutics (NASDAQ:AUTL) Shares Up 7.1% - Still a Buy?

Autolus Therapeutics logo with Medical background

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) were up 7.1% during mid-day trading on Monday . The company traded as high as $2.63 and last traded at $2.65. Approximately 779,759 shares were traded during trading, a decline of 50% from the average daily volume of 1,563,942 shares. The stock had previously closed at $2.47.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on AUTL shares. Needham & Company LLC reissued a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Thursday, June 12th. Truist Financial decreased their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Wells Fargo & Company lowered their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 21st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $9.32.

Get Our Latest Research Report on Autolus Therapeutics

Autolus Therapeutics Stock Performance

The stock has a market capitalization of $705.27 million, a price-to-earnings ratio of -3.01 and a beta of 1.81. The business's 50 day simple moving average is $1.92 and its 200-day simple moving average is $1.88.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. As a group, sell-side analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AUTL. AXA S.A. acquired a new position in Autolus Therapeutics during the 4th quarter worth $4,288,000. Armistice Capital LLC lifted its position in Autolus Therapeutics by 19.6% during the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock worth $17,050,000 after acquiring an additional 1,800,000 shares during the last quarter. Wellington Management Group LLP lifted its position in Autolus Therapeutics by 6.9% during the 1st quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company's stock worth $41,992,000 after acquiring an additional 1,746,020 shares during the last quarter. Millennium Management LLC lifted its position in Autolus Therapeutics by 91.6% during the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock worth $3,885,000 after acquiring an additional 790,437 shares during the last quarter. Finally, Atle Fund Management AB lifted its position in Autolus Therapeutics by 130.5% during the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company's stock worth $2,520,000 after acquiring an additional 625,817 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Autolus Therapeutics Right Now?

Before you consider Autolus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.

While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines